AML (Acute Myelogenous Leukemia
24
13
14
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
4.2%
1 terminated out of 24 trials
80.0%
-6.6% vs benchmark
4%
1 trials in Phase 3/4
50%
2 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 4 completed trials
Clinical Trials (25)
Umbilical Cord Blood Consolidation for Older Adults With Intermediate- and High-Risk AML
Salvage Chemotherapy With Sonrotoclax, Cladribine, and Standard-dose Cytarabine, Sequentially Followed by HSCT for R/R AML.
Efficacy and Safety of the CloB2M (Clofarabine Combined With Busulfan and Melphalan) Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients With Acute Myeloid Leukemia in First Complete Remission
Forecasting Relapse Outcomes With AlloHeme-based Risk Detection in Post-Allo-HCT AML/MDS Patients (FORWARD)
Fitness in Elderly AML Patients
Efficacy of Venetoclax Combined With Intensive Chemotherapy in Different Subgroups of AML
VEN+IDAC vs IDAC in AML
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials
A Phase 1 Study of CG009301 for Injection in Adult Subjects With Recurrent or Refractory Haematological Malignancies
Safety and Feasibility of Sulforaphane to Promote Early Haematopoietic Recovery After Cord Blood Transplantation
Correlation of Venetoclax Plasma Concentrations With Toxicity of Hypometilating Agents and Venetoclax Combination for Acute Myeloid Leukemia Patients in Remission.
Combination of HMA and Venetoclax With Posaconazole in Patients With Acute Myeloid Leukemia: A Study of Plasma Concentrations
The Efficacy of Therapy in Patients With Acute Myeloid Leukemia and Down Syndrome in Russia
The Efficacy and Safety Assessment of Allogeneic γδ T Cells in Patients With MRD-positive AML After Allo-HSCT
Clinical Trial of WBC100 Capsule in Relapsed/Refractory Acute Myeloid Leukemia
Use of Venetoclax , AML , Sohag , Egypt
The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors
Gut Health in Children With Cancer
Targeting Acute Myeloid Leukemia Immunosuppressive Microenvironment by combinedIDO1 Inhibition and PD-1 Blockade